Search Results

Philogen S.p.A announced that it has entered into a Service and Supply Agreement with IBSA to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena.

Philogen S.p.A. announces that it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD.

Sun Pharmaceutical Industries Limited and Philogen S.p.A announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ in the territories of Europe, Australia and New Zealand.

Philogen S.p.A. announces the publication of the latest results of Fibromun in combination with lomustine for the treatment of glioblastoma in Science Translational Medicine describing how the combination treatment cured orthotopic glioma-bearing mice and mediated durable objective responses and major tumor shrinkage in patients with recurrent glioblastoma.

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding recent corporate developments.

Philogen S.p.A. today announces that it will present at the UBS Global Healthcare Conference on May 25, 2022 at the Lotte New York Palace.

Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, announces the publication of a study in the peer-reviewed journal “Chem” describing the design, development and the in vivo characterization of novel OncoFAP ligands.